SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-17-003020
Filing Date
2017-01-05
Accepted
2017-01-05 16:40:04
Documents
9
Period of Report
2017-01-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d310875d8k.htm 8-K 40683
2 EX-2.1 d310875dex21.htm EX-2.1 588457
3 EX-3.1 d310875dex31.htm EX-3.1 70793
4 EX-10.1 d310875dex101.htm EX-10.1 39900
5 EX-10.2 d310875dex102.htm EX-10.2 46713
6 EX-10.3 d310875dex103.htm EX-10.3 20528
7 EX-10.4 d310875dex104.htm EX-10.4 70459
8 EX-99.1 d310875dex991.htm EX-99.1 18829
9 EX-99.2 d310875dex992.htm EX-99.2 8106
  Complete submission text file 0001193125-17-003020.txt   906021
Mailing Address 19820 NORTH CREEK PARKWAY SUITE 201 BOTHELL WA 98011
Business Address 19820 NORTH CREEK PARKWAY SUITE 201 BOTHELL WA 98011 425-686-1500
ONCOGENEX PHARMACEUTICALS, INC. (Filer) CIK: 0000949858 (see all company filings)

IRS No.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 033-80623 | Film No.: 17511279
SIC: 2835 In Vitro & In Vivo Diagnostic Substances